SCHEMBL14956104

SCHEMBL14956104

NC(=O)c1ncc(N[C@H]2CC[C@H](N)CC2)nc1Nc1cccc(-n2nccn2)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 19/20 0.75
▸ KCNH2 Q12809 4/20 0.75
▸ JAK2 O60674 2/20 0.53
▸ LCK P06239 2/20 0.53
▸ SRC P12931 2/20 0.53
▸ YES1 P07947 1/20 0.53
▸ LYN P07948 1/20 0.53
▸ FGR P09769 1/20 0.53
▸ PRKCA P17252 1/20 0.53
▸ FLT3 P36888 1/20 0.53
▸ ZAP70 P43403 1/20 0.53
▸ MAP3K9 P80192 1/20 0.53
▸ PAK5 Q9P286 1/20 0.53
▸ CDC7 O00311 1/20 0.53
▸ PLK4 O00444 1/20 0.53
▸ CHEK1 O14757 1/20 0.53
▸ PDPK1 O15530 1/20 0.53
▸ DAPK3 O43293 1/20 0.53
▸ DYRK3 O43781 1/20 0.53
▸ ROCK2 O75116 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14956102 1.00 SYK (0.75) SYKKCNH2JAK2LCKSRC
SCHEMBL14961937 1.00 SYK (0.75) SYKKCNH2JAK2LCKSRC
SCHEMBL14955262 0.87 SYK (0.69) SYKKCNH2JAK2LCKSRC
SCHEMBL14955264 0.87 SYK (0.69) SYKKCNH2JAK2LCKSRC
SCHEMBL14956172 0.86 SYK (1.00) SYKKCNH2JAK2LCKSRC
SCHEMBL14956594 0.84 MAPK1 (0.73) SYKKCNH2JAK2LCKSRC
SCHEMBL14961933 0.84 MAPK1 (0.73) SYKKCNH2JAK2LCKSRC
SCHEMBL14956595 0.84 MAPK1 (0.73) SYKKCNH2JAK2LCKSRC
SCHEMBL14955218 0.83 BTK (0.54) SYKKCNH2JAK2LCKSRC
SCHEMBL14955221 0.83 BTK (0.54) SYKKCNH2JAK2LCKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359308-B2 Pyrazine kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 — — US disclosed
US-8877760-B2 Substituted pyrazine-2-carboxamide kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2014-11-04 — — US disclosed
US-20140309209-A1 Pyrazine Kinase Inhibitors ALEXION PHARMACEUTICALS, INC. 2014-10-16 — — US disclosed
US-20130131040-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131040-A1 PYRAZINE KINASE INHIBITORS SYK, ZAP70, LCK SYK 1/4885KCNH2 1944/4885JAK2 29/4885
US-20140309209-A1 Pyrazine Kinase Inhibitors SYK, ZAP70, LCK SYK 1/4885KCNH2 1944/4885JAK2 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback